Murayama, Kayoko
Kiguchi, Toru
Izutsu, Koji
Kameoka, Yoshihiro
Hidaka, Michihiro
Kato, Harumi
Rai, Shinya
Kuroda, Junya
Ishizawa, Kenichi
Ichikawa, Satoshi
Ando, Kiyoshi
Ogura, Michinori
Fukushima, Koji
Terui, Yasuhito
Article History
Received: 5 October 2021
Accepted: 15 February 2022
First Online: 4 March 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Hokkaido University Hospital, Akita University Hospital, Tohoku University Hospital, Yamagata University Hospital, Fukushima Medical University Hospital, Dokkyo Medical University Hospital, Mito Medical Center, Gunma University Hospital, Gunma Prefectural Cancer Center, National Cancer Center Hospital, Cancer Institute Hospital, NTT Medical Center Tokyo, Aichi Cancer Center, Nagoya Medical Center, University Hospital Kyoto Prefectural University of Medicine, Osaka City University Hospital, Kindai University Hospital, Chugoku Central Hospital, Matsuyama Red Cross Hospital, Shimane University Hospital, Kyushu University Hospital, Kyushu Cancer Center, Nagasaki University Hospital, and Kumamoto Medical Center.
: Written informed consent was obtained from all of the patients who participated in the study.
: Written informed consent was obtained from all of the patients who participated in the study.
: T. Kiguchi reports research funds from SymBio Pharmaceuticals Limited. K. Izutsu reports personal fees from Janssen Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin Co., Ltd., and Eisai Co., Ltd. and research funds from AstraZeneca K.K., Abbvie, Eisai, Incyte Co., SymBio, Celgene Corporation, Novartis, Bayer, Janssen, Yakult, Kyowa Kirin, Ono, Zenyaku Kogyo, Daiichi Sankyo, Chugai, Beigene, and Genmab. H. Kato reports research funds from Zenyaku Kogyo, Chugai Pharmaceutical Co., Ltd., SymBio, Incyte, and Mundipharma and personal fees from SymBio. S. Rai reports personal fees from Chugai, Ono, and Janssen. J. Kuroda reports scholarship from Chugai. K. Ishizawa reports personal fees from Eisai, Novartis, Chugai, Celgene, Takeda Pharmaceutical Company Limited, Ono, IQVIA, Micron, Otsuka Pharmaceutical, Janssen, MSD, and Kyowa Kirin, SRD; research funds from Bayer, Otsuka, Pfizer, Sanofi, Abbvie, SymBio, Novartis, and IQVIA; and scholarship from Takeda. S. Ichikawa reports personal fee from AstraZeneca, and Chugai. K Ando reports research funds from Celgene, Novartis, and Astellas and scholarship from Chugai, Takeda, and Kyowa Kirin. M. Ogura reports personal fees from Meiji Seika Pharma. Y. Terui reports personal fees from Celgene, Janssen, MSD, Eisai, Ono, Takeda, Chugai, and Abbvie. K. Fukushima is an employee of SymBio. The rest of authors do not have any relationships to disclose.